In Press
#01
Review
Rituximab: What do we expect from difficult-to-treat nephrotic syndrome?
In the treatment of idiopathic nephrotic syndrome (INS) rituximab (RTX) as a chimeric CD20 blocker has been widely used. However, its efficacy in steroid-resist…